Patients with psoriatic arthritis-related enthesitis are more likely to persist on tofacitinib under real-life conditions

CONCLUSION: In this real-life study, tofacitinib showed a reasonably good retention rate in a PsA population mostly refractory to biologic and oral targeted-synthetic DMARDs. Patients with refractory PsA and enthesitis might be a specific target population for this drug. No new alarm signals emerged.PMID:38561189 | DOI:10.3899/jrheum.2024-0016

Source: J Rheumatol - April 1, 2024 Category: Rheumatology Authors: Ignacio Bra ña Marta Loredo Estefan ía Pardo Stefanie Burger Eva Fern ández-Bretón Rub én Queiro Source Type: research